T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Cervical Cancer|Renal Cancer|Melanoma|Bladder Cancer
Interventions: DRUG: Aldesleukin|DRUG: Fludarabine|DRUG: Cyclophosphamide|BIOLOGICAL: Anti-MAGE-A3 human leukocyte antigen serotype within HLA-A A serotype group (HLA-A* 01)-restricted T-cell receptor (TCR)
Sponsor: National Cancer Institute (NCI)